Effect of interferon combined with ganciclovir on immune status in children with infectious mononucleosis

To investigate the effect of interferon combined with ganciclovir on immune status in children with infectious mononucleosis(IM) and explore the clinical efficacy.

This was a retrospectively study. A total of 90 children with IM admitted to Baoding Hospital, Beijing Children's Hospital Affiliated to Capital Medical University from January 2022 to December 2023 were divided into the observation and control groups using a random number table. Afterward, the pre- and post-treatment humoral immunity indicators (IgG, IgA) and cellular immunity indicators (CD3+, CD4+, CD4+/CD8+) were compared between the observation and control groups.

IgG, IgA, CD3+, CD4+, and CD4+/CD8+ values in the observation group were significantly changed compared with those in the control group pre- and post-treatment, with statistical significance (p< 0.05); the post-treatment IgG, IgA, CD4+, and CD4+/CD8+ values in the two groups were significantly higher than the pre-treatment values, and CD3+ values were markedly lower than pre-treatment values, with statistical significance(p< 0.05); the post-treatment IgA and CD3+ values in the observation group were higher and lower than those in the control group, respectively, with statistical significance(p< 0.05).

Human interferon α-1b combined with ganciclovir in the treatment of IM leads to faster subsidence of clinical manifestation. Meanwhile, IgA and CD3+ are sensitive experimental indicators with certain clinical significance in evaluating the effect of IM, which can be used as a reference for evaluating the efficacy of drugs and disease outcomes.